- Home
- HIVE vs COLL Comparison
HIVE vs COLL Comparison
Compare HIVE & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- COLL
- Stock Information
- Founded
- HIVE 1987
- COLL 2002
- Country
- HIVE United States
- COLL United States
- Employees
- HIVE N/A
- COLL N/A
- Industry
- HIVE
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- HIVE
- COLL Health Care
- Exchange
- HIVE Nasdaq
- COLL Nasdaq
- Market Cap
- HIVE 933.9M
- COLL 958.8M
- IPO Year
- HIVE N/A
- COLL 2015
- Fundamental
- Price
- HIVE $5.90
- COLL $34.82
- Analyst Decision
- HIVE Strong Buy
- COLL Strong Buy
- Analyst Count
- HIVE 6
- COLL 4
- Target Price
- HIVE $7.67
- COLL $44.25
- AVG Volume (30 Days)
- HIVE 44.5M
- COLL 324.7K
- Earning Date
- HIVE 11-12-2025
- COLL 11-06-2025
- Dividend Yield
- HIVE N/A
- COLL N/A
- EPS Growth
- HIVE 42.43
- COLL N/A
- EPS
- HIVE 0.34
- COLL 1.06
- Revenue
- HIVE $128,649,000.00
- COLL $707,007,000.00
- Revenue This Year
- HIVE $190.37
- COLL $21.29
- Revenue Next Year
- HIVE $41.48
- COLL $3.36
- P/E Ratio
- HIVE $27.57
- COLL $33.34
- Revenue Growth
- HIVE 4.47
- COLL 22.61
- 52 Week Low
- HIVE $1.26
- COLL $23.23
- 52 Week High
- HIVE $7.84
- COLL $39.95
- Technical
- Relative Strength Index (RSI)
- HIVE 60.52
- COLL 52.14
- Support Level
- HIVE $4.74
- COLL $31.26
- Resistance Level
- HIVE $6.13
- COLL $36.11
- Average True Range (ATR)
- HIVE 0.69
- COLL 0.92
- MACD
- HIVE -0.14
- COLL 0.32
- Stochastic Oscillator
- HIVE 40.81
- COLL 74.02
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.